2.93

6.16% 0.17

After Hours: 2.88 -0.05 -1.71%

Estrella Immunopharma Inc (ESLA)

Overview News Price History Discussions Forecast

Estrella Immunopharma Inc stock is traded at $2.93, with a volume of 469.80K. It is up +6.16% in the last 24 hours and up +132.60% over the past month. Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.

Previous Close:

$2.76

Open:

$2.73

24h Volume:

469.80K

Relative Volume:

2.28

Market Cap:

$108.60M

Revenue:

Net Income/Loss:

$-8.82M

P/E Ratio:

-9.7667

EPS:

-0.3

Net Cash Flow:

$-18.01M

1W Performance:

+21.07%

1M Performance:

+132.60%

6M Performance:

+161.61%

1Y Performance:

+265.79%

1-Day Range:

$2.62

$3.01

1-Week Range:

$2.155

$3.15

52-Week Range:

$0.7001

$3.15

Estrella Immunopharma Inc Stock (ESLA) Company Profile

Name

Estrella Immunopharma Inc

Sector

Healthcare (1134)

Industry

Biotechnology (636)

Phone

(510) 318-9098

Address

5858 HORTON STREET, SUITE 370, EMERYVILLE

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ESLA's Discussions on Twitter

Compare ESLA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ESLA Estrella Immunopharma Inc	2.93	102.30M	0	-8.82M	-18.01M	-0.30
VRTX Vertex Pharmaceuticals Inc	409.47	105.61B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	657.53	67.99B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	442.70	58.19B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	854.65	52.40B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	189.70	39.60B	447.02M	-1.18B	-906.14M	-6.1812

Estrella Immunopharma Inc Stock (ESLA) Latest News

10:41 AM

How to integrate Estrella Immunopharma Inc. into portfolio analysis toolsPortfolio Gains Summary & High Accuracy Trade Signal Alerts - newser.com

10:41 AM

05:56 AM

What data driven models say about Estrella Immunopharma Inc.’s futurePortfolio Risk Report & Free Fast Gain Swing Trade Alerts - newser.com

05:56 AM

Nov 06, 2025

Estrella Immunopharma Achieves Milestone in STARLIGHT-1 Trial - TipRanks

Nov 06, 2025

[8-K] Estrella Immunopharma, Inc. Reports Material Event | ESLA SEC FilingForm 8-K - Stock Titan

Nov 06, 2025

Is Estrella Immunopharma Inc. stock oversold or undervaluedQuarterly Market Summary & AI Enhanced Execution Alerts - newser.com

Nov 06, 2025

Nov 05, 2025

Is Estrella Immunopharma Inc. reversing from oversold territoryJuly 2025 Macro Moves & Advanced Technical Signal Analysis - newser.com

Nov 05, 2025

Is Estrella Immunopharma Inc. building a consolidation basePortfolio Value Report & AI Powered Buy/Sell Recommendations - newser.com

Nov 05, 2025

Is Estrella Immunopharma Inc. stock ready for breakoutJuly 2025 Institutional & Consistent Profit Alerts - newser.com

Nov 05, 2025

Nov 04, 2025

Top 100 Stocks to Buy: Two Penny Stocks Moved Up 51 Spots. Should You Buy Either? - Barchart.com

Nov 04, 2025

Estrella Immunopharma's (ESLA) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat

Nov 04, 2025

Check out these key findings about Estrella Immunopharma Inc (ESLA) - setenews.com

Nov 04, 2025

Using data models to predict Estrella Immunopharma Inc. stock movementQuarterly Trade Report & Reliable Momentum Entry Alerts - newser.com

Nov 04, 2025

Estrella Immunopharma (NASDAQ:ESLA) Given “Buy” Rating at D. Boral Capital - Defense World

Nov 04, 2025

Analyst Jason Kolbert Maintains Buy Rating on ESLA | ESLA Stock News - GuruFocus

Nov 04, 2025

Nov 03, 2025

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients - BioSpace

Nov 03, 2025

Estrella Immunopharma stock soars after 100% complete response rate in trial - Investing.com Australia

Nov 03, 2025

Is now a turning point for Estrella Immunopharma Inc.Quarterly Portfolio Summary & Growth-Oriented Investment Plans - newser.com

Nov 03, 2025